SPP1+BCL2A1PD1

Chun-Hao Lai1, Yu-Ping Hung2, Po-Chun Tseng3

  • 1Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.

PubMed
概括

需要用于肝细胞癌 (HCC) 免疫治疗的新生物标志物. 研究人员确定SPP1+BCL2A1+TAMs是不良的预后标志物,可能改善ICB治疗反应预测.